BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 17616807)

  • 21. PAI-1 expression and its regulation by promoter 4G/5G polymorphism in clear cell renal cell carcinoma.
    Choi JW; Lee JH; Park HS; Kim YS
    J Clin Pathol; 2011 Oct; 64(10):893-7. PubMed ID: 21725041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urokinase-type plasminogen activator system and breast cancer (Review).
    Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
    Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker.
    Brendle A; Lei H; Brandt A; Johansson R; Enquist K; Henriksson R; Hemminki K; Lenner P; Försti A
    Carcinogenesis; 2008 Jul; 29(7):1394-9. PubMed ID: 18550570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels.
    Kathiresan S; Gabriel SB; Yang Q; Lochner AL; Larson MG; Levy D; Tofler GH; Hirschhorn JN; O'Donnell CJ
    Circulation; 2005 Sep; 112(12):1728-35. PubMed ID: 16172282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot AJ; van Tienoven DT; Beex LV; Sweep FC
    Thromb Haemost; 2004 Mar; 91(3):514-21. PubMed ID: 14983227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The -675 4G/5G polymorphism at the Plasminogen Activator Inhibitor 1 (PAI-1) gene modulates plasma Plasminogen Activator Inhibitor 1 concentrations in response to dietary fat consumption.
    Pérez-Martínez P; Adarraga-Cansino MD; Fernández de la Puebla RA; Blanco-Molina A; Delgado-Lista J; Marín C; Ordovás JM; López-Miranda J; Pérez-Jiménez F
    Br J Nutr; 2008 Apr; 99(4):699-702. PubMed ID: 17903340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
    Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
    Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
    De Cremoux P; Grandin L; Diéras V; Savignoni A; Degeorges A; Salmon R; Bollet MA; Reyal F; Sigal-Zafrani B; Vincent-Salomon A; Sastre-Garau X; Magdelénat H; Mignot L; Fourquet A;
    Anticancer Res; 2009 May; 29(5):1475-82. PubMed ID: 19443353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
    Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
    J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The influence of I/D polymorphism of the angiotensin I converting enzyme (ACE) gene and 4G/5G polymorphism of plasminogen activator inhibitor (PAI-1) gene promoter on the haemostatic system in patients with essential hypertension and dyslipidemia].
    Nowakowska A
    Ann Acad Med Stetin; 2005; 51(1):95-105. PubMed ID: 16496609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus.
    Funk M; Endler G; Exner M; Marculescu R; Endler L; Abrahamian H; Mauler H; Grimm A; Raith M; Mannhalter C; Prager R; Irsigler K; Wagner OF
    Wien Klin Wochenschr; 2005 Oct; 117(19-20):707-10. PubMed ID: 16416371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in Turkish patients with generalized aggressive periodontitis.
    Emingil G; Berdeli A; Gürkan A; Han Saygan B; Köse T; Atilla G
    J Clin Periodontol; 2007 Apr; 34(4):278-84. PubMed ID: 17257155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression.
    Lei H; Hemminki K; Altieri A; Johansson R; Enquist K; Hallmans G; Lenner P; Försti A
    Breast Cancer Res Treat; 2007 May; 103(1):61-9. PubMed ID: 17033924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension.
    Roncal C; Orbe J; Rodriguez JA; Belzunce M; Beloqui O; Diez J; Páramo JA
    Cardiovasc Res; 2004 Jul; 63(1):176-85. PubMed ID: 15194475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic importance of PAI-1 in node negative breast cancer patients--results after 10 years of follow up.
    Eljuga D; Razumovic JJ; Bulic K; Petrovecki M; Draca N; Bulic SO
    Pathol Res Pract; 2011 May; 207(5):290-4. PubMed ID: 21459526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.
    Meigs JB; Dupuis J; Liu C; O'Donnell CJ; Fox CS; Kathiresan S; Gabriel SB; Larson MG; Yang Q; Herbert AG; Wilson PW; Feng D; Tofler GH; Cupples LA
    Obesity (Silver Spring); 2006 May; 14(5):753-8. PubMed ID: 16855181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic value of BCAR1 in patients with primary breast cancer.
    Dorssers LC; Grebenchtchikov N; Brinkman A; Look MP; van Broekhoven SP; de Jong D; Peters HA; Portengen H; Meijer-van Gelder ME; Klijn JG; van Tienoven DT; Geurts-Moespot A; Span PN; Foekens JA; Sweep FC
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6194-202. PubMed ID: 15448007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients.
    Ezzidi I; Mtiraoui N; Chaieb M; Kacem M; Mahjoub T; Almawi WY
    Diabetes Metab; 2009 Jun; 35(3):214-9. PubMed ID: 19419896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
    Harbeck N; Thomssen C
    Zentralbl Gynakol; 2003 Sep; 125(9):362-7. PubMed ID: 14569518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.